715 related articles for article (PubMed ID: 10430100)
1. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
Guo B; Cao S; Tóth K; Azrak RG; Rustum YM
Clin Cancer Res; 2000 Feb; 6(2):718-24. PubMed ID: 10690558
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
McGuire JJ; Magee KJ; Russell CA; Canestrari JM
Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
[TBL] [Abstract][Full Text] [Related]
4. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
5. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
6. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Schultz RM; Patel VF; Worzalla JF; Shih C
Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
[TBL] [Abstract][Full Text] [Related]
7. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
8. Interaction of tomudex with radiation in vitro and in vivo.
Teicher BA; Ara G; Chen YN; Recht A; Coleman CN
Int J Oncol; 1998 Sep; 13(3):437-42. PubMed ID: 9683775
[TBL] [Abstract][Full Text] [Related]
9. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside.
Ashour OM; Naguib FN; Khalifa MM; Abdel-Raheem MH; Panzica RP; el Kouni MH
Cancer Res; 1995 Mar; 55(5):1092-8. PubMed ID: 7866994
[TBL] [Abstract][Full Text] [Related]
11. Polymer chemotherapy for head and neck cancer.
Shikani AH; Domb AJ
Laryngoscope; 2000 Jun; 110(6):907-17. PubMed ID: 10852503
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
[TBL] [Abstract][Full Text] [Related]
13. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
[TBL] [Abstract][Full Text] [Related]
14. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
[TBL] [Abstract][Full Text] [Related]
15. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase.
Huber BE; Austin EA; Good SS; Knick VC; Tibbels S; Richards CA
Cancer Res; 1993 Oct; 53(19):4619-26. PubMed ID: 8402637
[TBL] [Abstract][Full Text] [Related]
16. Cyclopropane-containing polyamine analogues are efficient growth inhibitors of a human prostate tumor xenograft in nude mice.
Frydman B; Blokhin AV; Brummel S; Wilding G; Maxuitenko Y; Sarkar A; Bhattacharya S; Church D; Reddy VK; Kink JA; Marton LJ; Valasinas A; Basu HS
J Med Chem; 2003 Oct; 46(21):4586-600. PubMed ID: 14521420
[TBL] [Abstract][Full Text] [Related]
17. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Cao S; Durrani FA; Rustum YM
Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action.
Porter CW; Bernacki RJ; Miller J; Bergeron RJ
Cancer Res; 1993 Feb; 53(3):581-6. PubMed ID: 8425191
[TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice.
Ishikawa Y; Kubota T; Otani Y; Watanabe M; Teramoto T; Kumai K; Kitajima M; Takechi T; Okabe H; Fukushima M
Clin Cancer Res; 1999 Apr; 5(4):883-9. PubMed ID: 10213225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]